Breakdown of oral hypoglycemic drug sales in hospitals in China 2018-2030, by agent

Of the overall oral antidiabetic drug sales in the key hospitals in China in 2018, slightly over half was contributed by acarbose and metformin. Beijing added a bunch of DDP-4 inhibitors like sitagliptin for reimbursement under government-backed insurance plans in 2017. With a drastic market growth in 2018, DDP-4 inhibitors were projected to take over acarbose as the leading revenue contributor in oral hypoglycemic medications in Chinese hospitals in 2030.

在2018年中国关键医院整体口服降糖药的销售中，略超过一半的贡献来自阿卡波糖和二甲双胍。2017年，北京政府保险计划下新增了诸如西格列汀等大量二肽基肽酶-4（DDP-4）抑制剂以供报销。随着2018年的市场剧增，预计到2030年，二肽基肽酶-4抑制剂将取代阿卡波糖，成为中国医院口服降糖药物中的主要收入贡献者。